Please login to the form below

Not currently logged in


This page shows the latest asthma news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra. ... NICE has published draft guidance recommending Fasenra (benralizumab), AstraZeneca’s treatment for people who have severe eosinophilic asthma.

Latest news

More from news
Approximately 59 fully matching, plus 477 partially matching documents found.

Latest Intelligence

  • Six degrees of participation Six degrees of participation

    individual. We can tell a GP in Hull that Joan in Stepney is not happy with her asthma care. ... If we know that Joan and others are unhappy with asthma services in Hull, let’s collaborate to determine what we can do to help.

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    Such monitoring could also allow for early prediction of treatment success, eg in a study to evaluate asthma treatment outcomes.

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    Asthma is one of the most significant non-communicable diseases of the 21st century. ... The two professors led The Lancet Clinical Commission, ‘After asthma: redefining airways diseases’in 2015.

  • US health reforms US health reforms

    To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by no means an outlier markdown.

More from intelligence
Approximately 2 fully matching, plus 33 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Telehealth Research

    Telehealth services are being used by more and more patients with chronic diseases such as asthma, COPD, diabetes and cardiovascular disease.

  • Raising Awareness: It’s World COPD Day today!

    7).The management of COPD could therefore be improved by limiting the use of ICS to the minority who might actually benefit; in particular COPD patients with asthma– COPD overlap syndrome ... Genetic background, clinical presentation, comorbidities,

  • Take a walk on the wild side!

    type 2 diabetes, asthma, stroke and some cancers.’ That’ s quite a list of benefits for something so simple!

  • Does wearable technology really have the potential to enhance modern healthcare?

    Apps available through HealthKit can track users’ health and allow doctors and patients to remotely monitor chronic diseases, such as diabetes and asthma. ... Another app aims to help people with asthma track their medical adherence and lung function.

  • A Bitter Pill?

    For lung diseases such as asthma and COPD, where inhalers are the most effective way to deliver medications to the target, this is particularly relevant because success is so dependent on

More from PMHub
Approximately 1 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...